Cryogenics logistics company Cryoport, Inc., will support TiGenix as it conducts its SEPCELL phase Ib/IIa clinical study to evaluate the safety and efficacy of expanded Cx611 allogeneic adipose‐derived stem cells (eASCs) for the treatment of sepsis in adult patients with severe community‐acquired bacterial pneumonia and admitted to the intensive care unit.
TiGenix, a global leader in allogeneic stem cell therapies targeting autoimmune diseases, aims to recruit 180 patients in at least 50 centres for the randomised double-blind placebo controlled SEPCELL study.
As a part of the agreement between the companies, Cryoport will provide global logistics support, observing international best practices for transporting cryogenically preserved clinical commodities. Cryoport’s suite of unique temperature controlled logistics solutions includes its Cryoport Express® shippers, SmartPak II™ Condition Monitoring System, Cryoportal™ Logistics Management Platform and 24/7/365 logistics support. These unparalleled capabilities will enable TiGenix to monitor its shipments and track the conditions and location of its stem cells while in transit, around the clock.
Jerrell Shelton, CEO of Cryoport, commented, “Sepsis is a potentially life-threatening complication of infection, which can lead to systemic inflammation and, in the worst cases, organ failure. The emergence of increasingly drug-resistant bacteria, alongside aging populations around the world, is driving a growing number of sepsis cases. TiGenix aims to leverage the anti-inflammatory properties found in stem cells to develop a novel treatment for sepsis, using its allogeneic (donor derived) stem cell platform, Cx611. We are, indeed, proud to be providing logistics support for this exciting clinical trial.”